BerGenBio appoints cancer drug development specialist Alan Barge MD as interim Chief Medical Officer
Further senior organisational changes made in preparation for advancing bemcentinib into the next stage of clinical development in multiple aggressive cancersBergen, Norway, 22nd November 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, is delighted to announce the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team. The Company also announces further senior organisational changes and a strengthening of its clinical operations as